Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sankyo/Cygnus settlement

This article was originally published in The Gray Sheet

Executive Summary

Sankyo Pharma agrees to pay $30 mil. to dissolve an agreement to distribute Cygnus' GlucoWatch G2 Biographer diabetes monitors in the U.S., companies announce Dec. 23. The settlement requires Sankyo to provide transition services related to product distribution for six months and to give Cygnus the title to its remaining inventory of GlucoWatch products, approximately 20,000 G2 Biographers and 1 mil. AutoSensors.Cygnus had sued Sankyo for breach of contract and laid off 60% of its workforce, following Sankyo's decision to terminate the deal (1"The Gray Sheet" Nov. 17, 2003, In Brief). Cygnus notes it is in discussions with potential distributors...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel